^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Sema4 Signal®

Company:
GeneDx
Type:
Laboratory Developed Test
Evidence

News

2ms
Altered expression of the Plexin-B2 system in tuberous sclerosis complex and focal cortical dysplasia IIb lesions. (PubMed, Histol Histopathol)
Furthermore, the expression of Plexin-B2 was positively correlated with seizure frequency in TSC and FCD IIb patients. In conclusion, our results showed the Plexin-B2-Sema4C system was abnormally expressed in cortical lesions of TSC and FCD IIb patients, signifying that the Plexin-B2-Sema4C system may play a role in the pathogenic development of TSC and FCD IIb.
Journal
|
Sema4 Signal®
5ms
Characterizing the role of Plexin-B receptor domains in synapse formation (Neuroscience 2023)
By examining the clustering and colocalization of presynaptic and postsynaptic molecules, we seek to determine whether the unique transmembrane domains of Plexin-B1 and Plexin-B2 may direct distinct steps of GABAergic and glutamatergic synapse development. Uncovering the functions of specific Plexin-B domains in synapse development will enhance our understanding of the signaling mechanisms that govern different steps in this process, as well as provide insight on how those processes differ between GABAergic and glutamatergic synapse development.
SEMA4D (Semaphorin 4D)
|
Sema4 Signal®
almost2years
Avera Health and Sema4 announce data-driven study to advance cancer treatment across the Avera service area (Sema4 Press Release)
"Avera Health...and Sema4...announced the Avera/Sema4 Oncology and Analytics Protocol (ASAP) study, a five-year commitment to population health for precision oncology care...Avera and Sema4 will leverage Sema4 Signal® Whole Exome/Transcriptome Sequencing (WES/WTS), which captures data from approximately 18,500 genes, to enable comprehensive molecular profiling of a patient’s tumor tissue. The ASAP study will also include Sema4 Signal® Hereditary Cancer, one of the most comprehensive hereditary cancer testing panels available, to inform better care decisions for individuals with and without a concurrent cancer diagnosis."
New trial
|
Sema4 Signal®
almost2years
Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape (AUA 2022)
There were no FDA-approved SDTs in prostate cancer (PCa) until 2020, when PARP inhibitors olaparib and rucaparib were approved for tumors bearing homologous recombination repair (HRR) genes. Increases in NGS test volume and olaparib use coincided with approval of PARP inhibitors for HRR-mutated PCa patients. Notably, NGS was used to match patients to off-label/investigational olaparib before its FDA approval.
Clinical • PARP Biomarker • Next-generation sequencing
|
HRD (Homologous Recombination Deficiency)
|
Sema4 Signal®
|
Lynparza (olaparib) • Rubraca (rucaparib)
2years
Sema4 announces nationwide expansion of disparity study to deliver precision oncology care to underserved communities (Sema4 Press Release)
"Sema4...announced the nationwide expansion of its disparities in cancer care study. The study, launched in 2021, enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities...The REsearch to advance PREciSion medicine and health Equity in oNcology Treatment (REPRESENT) study, which is already enrolling patients at five locations across two sites, will run nationally in collaboration with community oncologists caring for patients with advanced cancer in diverse and traditionally understudied and underserved populations."
Trial status
|
Sema4 Signal®